# CHAPTER 6

# AI IN NATURAL PRODUCT DRUG DISCOVERY

Author

*Mrs. Sreedevi Kudaravalli, Associate Professor,*
*Department of Pharmaceutical Biotechnology, Sultan-ul-Uloom College of Pharmacy, Banjara Hills, Hyderabad, Telangana, India*

**Abstract**

Revitalizing the pipeline for natural product drug discovery requires overcoming the historical challenges of structural complexity and isolation difficulty through computational innovation. Artificial Intelligence catalyzes this process by constructing and screening massive virtual libraries of natural products, utilizing deep learning to predict binding affinities against novel biological targets. This approach facilitates target deconvolution, identifying the precise molecular mechanisms of bioactive extracts through network pharmacology and inverse docking strategies that map ligand-protein interactions. Generative models further enhance this by designing *de novo* drug candidates inspired by natural scaffolds, utilizing reinforcement learning to optimize them for improved bioavailability and reduced toxicity. In the context of traditional medicine, AI modernizes the use of herbal formulations by predicting potential herb-drug interactions through the mining of biomedical literature and clinical data, thereby preventing adverse clinical events. Optimization algorithms simulate complex polyherbal mixtures to identify synergistic combinations where ingredients amplify each other's therapeutic effects while minimizing off-target toxicity. This rational design process bridges the gap between ancient botanical wisdom and modern evidence-based pharmacotherapy, delivering standardized, efficacious, and safe natural health products that meet the rigorous demands of modern healthcare systems.

***Keywords:*** *Network Pharmacology, Inverse Docking, Scaffold Hopping, Herb-Drug Interactions (HDIs), Virtual Libraries, Synergistic Formulations*

**Learning Objectives**

After completion of the chapter, the learners should be able to:

- Describe the process of target deconvolution and how AI identifies the molecular mechanisms of bioactive extracts.
- Illustrate the use of "inverse docking" strategies to map natural product ligands to potential disease targets.
- Examine the potential for herb-drug interactions by analyzing data mined from biomedical literature via NLP.
- Assess the potential of Network Pharmacology in rationalizing and optimizing synergistic polyherbal formulations.
- Design a *de novo* drug candidate by computationally modifying a natural product scaffold to improve its pharmaceutical properties.

## AI-DRIVEN DRUG DISCOVERY FROM NATURAL PRODUCTS

Natural products have served as the single most productive source of leads for the development of drugs, contributing to over half of all FDA-approved small-molecule medicines in cancer and infectious disease. Despite this historical success, the pharmaceutical industry largely retreated from natural product research in the late 20th century due to technical hurdles: the structural complexity of these molecules, difficulties in isolation, and supply chain instability. Artificial Intelligence has catalyzed a renaissance in this field, effectively resolving these historical bottlenecks. AI algorithms process the immense structural diversity of nature's chemical library, translating complex biological data into actionable therapeutic candidates. This computational resurgence allows researchers to bypass the laborious "grind-and-find" approach, replacing it with a targeted, rational discovery pipeline that leverages the evolutionary optimization already present in natural metabolites.

*Building and Screening Large Virtual Libraries of Natural Products*

The starting point for AI-driven discovery is the construction of massive virtual chemical libraries. Physical screening of natural products is limited by the availability of biological material; many promising sponges or rare plants cannot be harvested in sufficient quantities for high-throughput assays. Virtual libraries digitize this chemical space. Researchers aggregate data from ethnobotanical records, scientific literature, and chemical databases (such as COCONUT, NPAtlas, or TCMDatabase@Taiwan) to create digital repositories containing millions of natural product structures and their synthesized analogs. These databases utilize specific notation formats like Simplified Molecular Input Line Entry System (SMILES) or International Chemical Identifier (InChI) to represent the 3D stereochemistry of complex terpenes and alkaloids in a machine-readable string format.

Screening these libraries requires sophisticated computational filters that go beyond simple similarity searching. Deep learning models, specifically Graph Convolutional Networks (GCNs) and Message Passing Neural Networks (MPNNs), analyze the molecular topology of these virtual compounds. These networks treat atoms as nodes and chemical bonds as edges, passing information between neighbors to learn a high-dimensional representation of the molecule's bioactivity.




**Figure 6.1: Graph Neural Networks (GNN) for Predicting Bioactivity**

The AI learns to predict the binding affinity of a molecule against a specific disease target, such as a viral protease or a kinase involved in cancer metastasis. Unlike traditional

molecular docking, which is computationally expensive and struggles with the flexibility of the protein backbone, deep learning scoring functions can screen millions of compounds in hours. They account for non-covalent interactions like Van der Waals forces and electrostatic bridges with high precision. This rapid prioritization process identifies "hit" compounds with high predicted potency, allowing chemists to focus their synthetic or extraction efforts only on the most promising candidates, drastically reducing the attrition rate in early-stage discovery.

**Table 6.1: Classical vs. AI-Driven Discovery Pipeline**

| Stage | Classical Pharmacognosy | AI-Driven Discovery | Efficiency Gain |
|---|---|---|---|
| **Library** | Physical Extracts | Virtual Chemical Libraries | $10^6$ vs $10^9$ compounds scanned. |
| **Screening** | Bioassay-guided fractionation | Virtual Screening (Docking/GNN) | Weeks → Hours. |
| **Target ID** | Difficult (Phenotypic) | Target Deconvolution (Network) | Rapid mechanism elucidation. |
| **Analogs** | Semi-synthesis (Manual) | Generative Design (GANs) | Explores non-obvious chemical space. |
| **Safety** | Animal Toxicology | *In Silico* ADMET | Early rejection of toxic leads. |

*AI for Identifying Novel Biological Targets (Target Deconvolution)*

A persistent challenge in natural product pharmacology is phenotypic discovery: identifying an extract that cures a disease without knowing the underlying molecular mechanism. Determining the specific protein target of a bioactive compound known as target deconvolution is essential for regulatory approval and toxicity management. AI solves this through "inverse docking" and network pharmacology approaches. Instead of fitting many ligands to one receptor, the algorithm fits one bioactive ligand against a proteome-wide database of

thousands of protein structures (the human "druggable" genome).




**Figure 6.2: Network Pharmacology: Decoding Synergy**

Machine learning models trained on large drug-target interaction datasets (like ChEMBL or BindingDB) utilize similarity searching and substructure analysis to predict likely targets. If a novel sesquiterpene lactone shares critical 3D pharmacophore features with a known NF-kB inhibitor, the AI predicts this pathway as the mechanism of action. Advanced systems integrate transcriptomic data, observing how the compound alters gene expression profiles in treated cells. Pattern recognition algorithms compare these expression signatures against databases of known drug responses (like the Connectivity Map), identifying the biological target through "guilt-by-association." This capability transforms "black box" herbal remedies into well-characterized therapeutic agents with defined mechanisms. It allows researchers to map the poly-pharmacology of natural products, revealing how a single compound might modulate multiple targets simultaneously (e.g., inhibiting COX-2 while activating Nrf2), a common feature of multi-functional natural metabolites.

*De Novo Design of New Drug Candidates Inspired by Natural Product Scaffolds*

Nature provides excellent starting points, but natural products often possess suboptimal pharmaceutical properties, such as poor solubility, metabolic instability, or rapid clearance. AI-driven *de novo* design utilizes natural product scaffolds not

as final drugs, but as evolutionary blueprints. Generative AI models, such as Recurrent Neural Networks (RNNs) and Variational Autoencoders (VAEs), are trained on the structural rules of natural chemistry. These models generate millions of novel molecular structures that retain the bioactive core of the natural product while optimizing its periphery for drug-like properties (following Lipinski's Rule of Five).

**Table 6.2: Network Pharmacology & Biological Meaning**

| Graph | Definition | Biological Interpretation in Herbal Medicine |
|---|---|---|
| **Node Degree** | Number of connections a node has. | **Hubs**: Compounds targeting many proteins (Pleiotropy) or Proteins targeted by many herbs. |
| **Betweenness** | Frequency a node acts as a bridge. | **Bottlenecks**: Proteins that control signal flow between different disease pathways. |
| **Closeness** | Avg. distance to all other nodes. | **Speed**: How quickly a drug perturbation spreads through the metabolic network. |
| **Module** | Cluster of densely connected nodes. | **Synergy**: A group of herbs acting on a specific functional unit (e.g., Inflammation module). |
| **Edge Weight** | Strength of interaction. | **Potency**: Binding affinity (Kd) or confidence of the prediction. |

This process is often termed "scaffold hopping." The AI might take the complex macrocyclic ring of a marine peptide and computationally "mutate" it, replacing unstable ester bonds with bioisosteres (like amides) that improve oral bioavailability. Reinforcement learning agents guide this generation process. The agent is rewarded for generating structures that maintain high binding affinity to the target while simultaneously minimizing predicted toxicity and maximizing synthesis feasibility. Consequently, the system evolves "pseudo-natural products" molecules that look and behave like nature-derived compounds but are chemically novel, patentable, and optimized for modern clinical use. This effectively bridges the gap between the chemical diversity of the biosphere and the stringent

requirements of modern pharmacotherapy.

**Applications in Herb Identification, Herb-Drug Interactions, and Herbal Formulations**

The integration of AI extends beyond single-molecule discovery to the modernization of traditional herbal medicine systems. Ensuring the identity of raw materials and understanding the complex interactions within polyherbal mixtures are critical for safety. AI provides the tools to standardize these inherently variable biological products, bridging the gap between traditional wisdom and evidence-based medicine.

*AI-Powered Databases and Mobile Apps for Plant Identification*

Accurate identification of medicinal plants is the first step in the value chain. Misidentification leads to the use of ineffective or toxic substitutes (e.g., confusing *Stephania tetrandra* with the nephrotoxic *Aristolochia fangchi*). AI-powered computer vision has democratized botanical expertise through mobile applications. These platforms utilize Convolutional Neural Networks (CNNs) trained on millions of geotagged plant images. A user captures an image of a leaf, flower, or bark, and the AI analyzes morphological features leaf margin dentation, venation pattern, phyllotaxy, and trichome density to classify the species with high accuracy.




**Figure 6.3: Predicting Herb-Drug Interactions via NLP**